Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extramedullary AML: Clinical and Molecular Features.

Cancers·2026

Same author

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Hematological oncology·2026

Same author

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Current oncology (Toronto, Ont.)·2026

Same author

Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.

British journal of haematology·2025

Same author

What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?

Clinical lymphoma, myeloma & leukemia·2025

Same author

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

The Lancet. Haematology·2025

Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026

Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026

Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026

Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026

Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026

Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 24, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

ENMD-2076 for hematological malignancies.

Jonathan How¹, Karen Yee

¹Medical Oncology & Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada. karen.yee@uhn.ca

Expert Opinion on Investigational Drugs

|March 9, 2012

Summary

This summary is machine-generated.

ENMD-2076, a multi-kinase inhibitor targeting Aurora kinases, shows promise in treating hematological malignancies like acute myeloid leukemia and multiple myeloma. Further research is recommended to explore its combination with other therapies.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: May 24, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

Oncology
Hematology
Molecular Biology

Background:

Aurora kinases are crucial for mitosis, making their inhibition a viable cancer treatment strategy.
Solid tumors and hematological malignancies are key targets for Aurora kinase inhibitors.

Purpose of the Study:

To summarize preclinical and clinical data for ENMD-2076 in hematological malignancies.
To assess the efficacy and tolerability of ENMD-2076 in treating blood cancers.

Main Methods:

Searched MEDLINE (1980-2012) and conference proceedings (ASCO, ASH 1997-2011) for ENMD-2076 in hematological cancers.
Included terms: Aurora, multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms.

Main Results:

ENMD-2076 is a multi-kinase inhibitor targeting Aurora A, FLT3, c-KIT, c-FMS, and VEGFR-2/3.
The drug demonstrated tolerability and favorable pharmacokinetics.
Activity was observed in patients with acute myeloid leukemia and multiple myeloma.

Conclusions:

ENMD-2076 shows potential as a treatment for certain hematological malignancies.
Further investigation combining ENMD-2076 with chemotherapy and other targeted agents is warranted.
Combination therapies should target different pathways with non-overlapping toxicities.